Results 201 to 210 of about 24,520 (233)

Expression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy

American Journal of Clinical Pathology
Abstract Objectives Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.
Jingjing Zhang, Philip L Bulterys, Sebastian Fernandez-Pol, Sheren F Younes, Shuchun Zhao, Adnan Mansoor, Yasodha Natkunam   +6 more
openaire   +2 more sources

CD47

AfCS-Nature Molecule Pages, 2010
William Frazier, Jeffrey Isenberg, Sukhbir Kaur, David Roberts   +3 more
openaire   +1 more source

The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions

Cancer Cell, 2023
Juan C Osório, David Knorr, Jeffrey Ravetch   +2 more
exaly  

CD47

1997
A. Neil Barclay, Marion H. Brown, S.K. Alex Law, Andrew J. McKnight, Michael G. Tomlinson, P. Anton van der Merwe   +5 more
openaire   +1 more source

CD47

2016
David D. Roberts, Jeffrey S. Isenberg, David R. Soto-Pantoja   +2 more
openaire   +1 more source

CD47

2018
David D. Roberts, Jeffrey S. Isenberg, David R. Soto-Pantoja   +2 more
openaire   +1 more source

CD47: Beyond an immune checkpoint in cancer treatment

Biochimica Et Biophysica Acta: Reviews on Cancer, 2022
Dale Nagle, Xin Luan
exaly  

The CD47-SIRPα axis is a promising target for cancer immunotherapies

International Immunopharmacology, 2023
Yiling Li, Xinxuan Zhou
exaly  

Extracellular Vesicles‐Derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy

Advanced Materials, 2023
Xing-Jie Liang
exaly  

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

Annual Review of Immunology, 2014
Timo Van Den Berg
exaly